JP2016128399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128399A5 JP2016128399A5 JP2015118495A JP2015118495A JP2016128399A5 JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5 JP 2015118495 A JP2015118495 A JP 2015118495A JP 2015118495 A JP2015118495 A JP 2015118495A JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- lipophilic
- amino acids
- group
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/075722 WO2016091487A1 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| US15/534,800 US11083774B2 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| EP15793746.7A EP3230318B1 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| DK15793746.7T DK3230318T3 (da) | 2014-12-11 | 2015-11-04 | Immune checkpoint-inhibitor-kombinationer |
| AU2015359881A AU2015359881B2 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| HUE15793746A HUE051268T2 (hu) | 2014-12-11 | 2015-11-04 | Immunellenõrzõpont-gátló kombinációk |
| LTEP15793746.7T LT3230318T (lt) | 2014-12-11 | 2015-11-04 | Imuninės kontrolės taško inhibitorių kombinacijos |
| PL15793746T PL3230318T3 (pl) | 2014-12-11 | 2015-11-04 | Kombinacje inhibitora immunologicznego punktu kontrolnego |
| PT157937467T PT3230318T (pt) | 2014-12-11 | 2015-11-04 | Combinações de inibidores de pontos de controlo imunitários |
| ES15793746T ES2819282T3 (es) | 2014-12-11 | 2015-11-04 | Combinaciones de inhibidores de puntos de control inmunitarios |
| AU2019203199A AU2019203199B2 (en) | 2014-12-11 | 2019-05-07 | Immune checkpoint inhibitor combinations |
| AU2021204356A AU2021204356B2 (en) | 2014-12-11 | 2021-06-25 | Immune checkpoint inhibitor combinations |
| US17/366,463 US20230201305A9 (en) | 2014-12-11 | 2021-07-02 | Immune checkpoint inhibitor combinations |
| US18/598,719 US12239686B2 (en) | 2014-12-11 | 2024-03-07 | Immune checkpoint inhibitor combinations |
| US19/022,157 US20250332217A1 (en) | 2014-12-11 | 2025-01-15 | Immune checkpoint inhibitor combinations |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1422084.2 | 2014-12-11 | ||
| GB201422084 | 2014-12-11 | ||
| GB1506127.8 | 2015-04-10 | ||
| GBGB1506127.8A GB201506127D0 (en) | 2015-04-10 | 2015-04-10 | Immune checkpoint inhibitor combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128399A JP2016128399A (ja) | 2016-07-14 |
| JP2016128399A5 true JP2016128399A5 (enExample) | 2018-05-10 |
| JP6767096B2 JP6767096B2 (ja) | 2020-10-14 |
Family
ID=56384106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015118495A Active JP6767096B2 (ja) | 2014-12-11 | 2015-06-11 | 免疫チェックポイント阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11083774B2 (enExample) |
| EP (1) | EP3230318B1 (enExample) |
| JP (1) | JP6767096B2 (enExample) |
| AU (3) | AU2015359881B2 (enExample) |
| DK (1) | DK3230318T3 (enExample) |
| ES (1) | ES2819282T3 (enExample) |
| HU (1) | HUE051268T2 (enExample) |
| LT (1) | LT3230318T (enExample) |
| PL (1) | PL3230318T3 (enExample) |
| PT (1) | PT3230318T (enExample) |
| WO (1) | WO2016091487A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| US11666646B2 (en) | 2016-12-26 | 2023-06-06 | National University Corporation Kobe University | Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor |
| WO2018188761A1 (en) * | 2017-04-13 | 2018-10-18 | Lytix Biopharma As | Method of reducing population size of tregs and/or mdscs |
| US11759485B2 (en) | 2018-06-14 | 2023-09-19 | Meiji Co., Ltd. | Composition for enhancing immune checkpoint blockade therapy |
| US11266643B2 (en) | 2019-05-15 | 2022-03-08 | Chemocentryx, Inc. | Triaryl compounds for treatment of PD-L1 diseases |
| EP3986392A4 (en) * | 2019-06-20 | 2023-07-12 | ChemoCentryx, Inc. | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES |
| CN110317245B (zh) * | 2019-08-02 | 2021-04-09 | 郑州大学 | Lag-3蛋白亲和环肽及其应用 |
| US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| WO2021142088A1 (en) * | 2020-01-07 | 2021-07-15 | The Trustees Of The University Of Pennsylvania | Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies |
| CN120731083A (zh) | 2022-12-20 | 2025-09-30 | 莱特克斯生物制药股份有限公司 | 包含溶瘤肽和壳聚糖的组合物 |
| AU2023413677A1 (en) | 2022-12-20 | 2025-06-19 | Lytix Biopharma As | Medical products containing an aqueous formulation of a peptide |
| CN117402828A (zh) * | 2023-04-13 | 2024-01-16 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种人肺癌脑转移瘤细胞系及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| AU3786999A (en) | 1998-05-04 | 1999-11-23 | Thomas Jefferson University | Composition comprising tumor cells and extracts and method of using thereof |
| GB0605685D0 (en) * | 2006-03-21 | 2006-05-03 | Lytix Biopharma As | Inhibition of tumour growth |
| PT1537878E (pt) * | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| GB0821616D0 (en) | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
| CN104826106B (zh) | 2009-09-30 | 2019-01-11 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| US9410206B2 (en) * | 2011-11-30 | 2016-08-09 | John Wayne Cancer Institute | Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer |
| AU2014339900B2 (en) * | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| WO2015127407A1 (en) * | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| EP3230498B1 (en) * | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| JP6813258B2 (ja) * | 2014-12-11 | 2021-01-13 | リティックス バイオファーマ エイエス | 化学療法の組み合わせ |
-
2015
- 2015-06-11 JP JP2015118495A patent/JP6767096B2/ja active Active
- 2015-11-04 WO PCT/EP2015/075722 patent/WO2016091487A1/en not_active Ceased
- 2015-11-04 ES ES15793746T patent/ES2819282T3/es active Active
- 2015-11-04 DK DK15793746.7T patent/DK3230318T3/da active
- 2015-11-04 PT PT157937467T patent/PT3230318T/pt unknown
- 2015-11-04 HU HUE15793746A patent/HUE051268T2/hu unknown
- 2015-11-04 LT LTEP15793746.7T patent/LT3230318T/lt unknown
- 2015-11-04 AU AU2015359881A patent/AU2015359881B2/en active Active
- 2015-11-04 EP EP15793746.7A patent/EP3230318B1/en active Active
- 2015-11-04 US US15/534,800 patent/US11083774B2/en active Active
- 2015-11-04 PL PL15793746T patent/PL3230318T3/pl unknown
-
2019
- 2019-05-07 AU AU2019203199A patent/AU2019203199B2/en active Active
-
2021
- 2021-06-25 AU AU2021204356A patent/AU2021204356B2/en active Active
- 2021-07-02 US US17/366,463 patent/US20230201305A9/en not_active Abandoned
-
2024
- 2024-03-07 US US18/598,719 patent/US12239686B2/en active Active
-
2025
- 2025-01-15 US US19/022,157 patent/US20250332217A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104853776B (zh) | 免疫应答的增强 | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| JP2018501197A5 (enExample) | ||
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| JP2015504871A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2016527286A5 (enExample) | ||
| JP2016539096A5 (enExample) | ||
| JP2017508744A5 (enExample) | ||
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| AU2021203564B2 (en) | Compositions comprising naphthyridine derivatives and aluminium adjuvant for use in treating solid tumors | |
| JP2017503014A5 (enExample) | ||
| BR112018001534A2 (pt) | inibidor de isocitrato desidrogenase idh1 r132h mutante | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA202090959A1 (ru) | Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| AU2018360386A1 (en) | Dual inhibitors of TIM-3 and PD-1 pathways | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| JP2022518232A5 (enExample) | ||
| RU2011123700A (ru) | Нонапептид с противоопухолевой активностью | |
| JP2018519324A5 (enExample) | ||
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| JP2024133495A (ja) | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール | |
| EP3209328B1 (en) | Inhibitors of lactate transporters for use in the treatment of inflammatory diseases |